Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials

Philip J. Rosenfeld, Howard Shapiro, Lisa Tuomi, Mary Webster, Julee Elledge, Barbara Blodi

Research output: Contribution to journalArticle

190 Scopus citations

Fingerprint Dive into the research topics of 'Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials'. Together they form a unique fingerprint.

Medicine & Life Sciences